Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 Study.

Trial Profile

Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 27 Jul 2017 Results of a post-hoc pooled analysis of safety data from NCT00957684, NCT00957047, NCT00957372 NCT00988429, NCT02281422, NCT02281526 and NCT01422720 studies published in the Drug Safety
    • 02 Dec 2015 Post-hoc analysis results from three phase III trials presented at the 69th Annual Meeting of the American Epilepsy Society (AES), according to a Sunovion Pharmaceuticals media release.
    • 15 Jul 2014 According to a Bial media release, eslicarbazepine acetate was approved in EU on the basis of efficacy and safety data from this trial, a phase II trial (see profile 700154544) and 3 other phase III trials (see profiles 70037569, 70037570, and 70049692.)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top